Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 10Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 989Neoplasms 848Carcinoma, Non-Small-Cell Lung 842Prostatic Neoplasms 527Neoplasm Metastasis 500Leukemia, Myeloid, Acute 488Melanoma 453Colorectal Neoplasms 446Multiple Myeloma 440Lung Neoplasms 419Pancreatic Neoplasms 352Recurrence 350Lymphoma 349Ovarian Neoplasms 341Lymphoma, Non-Hodgkin 327Leukemia 323Leukemia, Lymphocytic, Chronic, B-Cell 301Precursor Cell Lymphoblastic Leukemia-Lymphoma 271Carcinoma, Renal Cell 256Head and Neck Neoplasms 246Brain Neoplasms 243Carcinoma, Hepatocellular 234Squamous Cell Carcinoma of Head and Neck 231Glioblastoma 231Myelodysplastic Syndromes 229Lymphoma, Large B-Cell, Diffuse 228Lymphoma, Follicular 219Colonic Neoplasms 191Stomach Neoplasms 182Rectal Neoplasms 175

Interventions

YF 476 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Interventional × Zollinger-Ellison Syndrome × Clear all
NCT02454075 2021-01-29

YF476 and Type II Gastric Carcinoids

Trio Medicines Ltd.

Phase 2 Terminated
3 enrolled 11 charts

Zollinger-Ellison Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡